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A recombinant multi-stage vaccine against paratuberculosis significantly reduces 
bacterial level in tissues without interference in diagnostics  
 
G Jungersen, A Thakur, C Aagaard, H Mikkelsen, P Andersen  
National Veterinary Institute, Technical University of Denmark, and Statens Serum 
Institute, Copenhagen, Denmark 
 
A new (FET11) recombinant vaccine against paratuberculosis was developed based on 
recombinant antigens from acute and latent stages of Mycobacterium avium subsp. 
paratuberculosis (Map) infection. 
 
In two experiments 28 calves and 15 goats were orally inoculated with live Map in their 
third week of life and post-exposure vaccinated at different times after inoculation or with 
different vaccine constructs. In contrast to common whole-cells vaccination, the FET11 
vaccine did not interfere with tests for paratuberculosis or bovine tuberculosis as no 
measurable antibody responses by ID Screen® ELISA, PPDj-specific IFN-γ responses or 
positive PPDa or PPDb skin tests developed in vaccinees. Antibodies and cell-mediated 
immune responses were developed against FET11 antigens, however. At necropsy 8 or 
12 months of age, relative Map burden was determined in a number of gut tissues by 
quantitative IS900 PCR and revealed significantly reduced levels of Map and reduced 
histopathology. Diagnostic tests for antibody responses and cell-mediated immune 
responses, used as surrogates of infection, corroborated the observed vaccine efficacy: 
Five of seven non‐vaccinated calves seroconverted in ID Screen® ELISA at 32 to 40 
weeks p.i. indicating the progression of infection, while only four of 14 FET11 vaccinated 
calves seroconverted at 40-52 weeks p.i. Similarly, PPDj-induced IFN‐γ responses 
increased over time in non-vaccinated calves, while FET11 vaccinated calves had 
significantly reduced PPDj IFN-γ assay responses from 40 to 52 weeks compared to non-
vaccinated calves. These results indicate the FET11 vaccine can be used to accelerate 
eradication of paratuberculosis while surveillance or test-and-manage control programs for 
tuberculosis and Johne’s disease remain in place.  
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